Breaking news! Wizbiotech secures the 2nd FOB self test certificate in China
On August 23th, 2024, Wizbiotech has secured the second FOB (Fecal Occult Blood) self-testing certificate in China. This achievement signifies Wizbiotech’s leadership in the burgeoning field of at-home diagnostic testing, a trend accelerated by the global health crisis COVID-19.
The FOB test is a critical diagnostic procedure used to detect abnormalities in the gastrointestinal tract, particularly in the early screening of colorectal cancer. The FOB test collects stool as sample, which makes it difficult to be run at hospital or clinic. In China, when patient was asked to collect stool for this test, there will be about 50% possibility to be abandoned. However, if this test can be done at home, the problem of abandon rate will be greatly solved. Therefore, an FOB self-test product will not only enhance the colorectal cancer screening rate but also contribute to the broader goal of making healthcare more accessible and efficient.
This certification is expected to significantly expand Wizbiotech’s market reach, as the demand for home diagnostic tests surges. With the Chinese IVD market projected to grow rapidly, Wizbiotech is poised to capture a substantial share of this expanding market, according to insights from industry analysts.
About Wizbiotech
Wizbiotech is a leading in vitro diagnostics company committed to developing innovative diagnostic solutions for gastrointestinal health. With a focus on early detection and prevention, Wizbiotech is dedicated to improving the availability of medical service and advancing the field of medical diagnostics.
